A Nonsynonymous Polymorphism in IRS1 Modifies Risk of Developing Breast and Ovarian Cancers in BRCA1 and Ovarian Cancer in BRCA2 Mutation Carriers

Grants

Funding Acknowledgements

Beckman Research Institute of the City of Hope (BRICOH) study was supported by NIH R01CA74415 (S.L. Neuhausen) and P30CA033752. S.L. Neuhausen is the Morris and Horowitz Families Endowed Professor. Sheba Medical Center Study (SMC) was in part sponsored by a grant from the Israel cancer association to E. Friedman on behalf of the Israeli consortium of inherited breast cancer. University of Pennsylvania (UPENN) study was supported by R01-CA083855 and R01-CA102776 (T. R. Rebbeck). Spanish National Cancer Center (CNIO) study has been partially funded by Mutua Madrilena Foundation, "Red de Investigacion en Cancer RD06/0020/1160", and Spanish Ministry of Science and Innovation (FIS P1081120 and SAF2010-20493). Epidemiologic study of BRCA1 and BRCA2 mutation carriers (EMBRACE) is supported by Cancer Research UK Grants C1287/A10118 and C1287/A11990. D.G. Evans and F. Lalloo are supported by an NIHR grant to the Biomedical Research Centre (Manchester, UK). The Investigators at The Institute of Cancer Research and The Royal Marsden NMS Foundation Trust are supported by an NIHR grant to the Biomedical Research Centre at The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust. R. Eeles and E. B. Gomez Garcia are supported by Cancer Research UK Grant C5047/A8385. Fox Chase Cancer Center (FCCC) study was supported by R01CA140323, U01CA69631, and 5U01CA113916 (to A.K. Godwin). Copenhagen Breast Cancer Study (CBCS) was supported by the NEYE Foundation. Gynecologic Oncology Group (COG) was supported through funding provided by both intramural (Clinical Genetics Branch, DCEG) and extramural (Community Oncology and Prevention Trials Program-COPTRG) National Cancer Institute (NCI) programs, and was based in GOG's Cancer Prevention and Control Committee. N.N. Petrov Institute of Oncology (NNPIO) study is supported by the Russian Foundation for Basic Research (grants 10-04-92110, 10-04-92601, and 11-04-00227), the Federal Agency for Science and Innovations (contract 02.740.11.0780), and through a Royal Society International Joint Grant (JP090615). The Baltic Familial Breast and Ovarian Cancer Consortium (BFBOCC, Latvia and Lithuania) study is supported by the Research Council of Lithuania grant LIG-19/2010 to R.J. Institut Catala d'Oncologia (ICO); Asociacion Espanola Contra el Cancer, Spanish Health Research Fund; Carlos III Health Institute; Catalan Health Institute, and Autonomous Government of Catalonia. Contract grant numbers: ISCIIIRETIC RD06/0020/1051, PI10/01422, PI10/31488, and 2009SGR290. UK and Gilds Radner Familial Ovarian Cancer Registries (UKGRFOCR) study was supported by a project grant from CRUK (to P. Peterlongo). Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute (WCP) is supported by American Cancer Society (120950-SIOP-06-258-06-COUN). The German Consortium of Hereditary Breast and Ovarian Cancer (GC-HBOC) was supported by a grant of the German Cancer Aid (DKH 109076). Helsinki Breast Cancer Study (HEBCS) was supported by the Helsinki University Central Hospital Research Fund, Academy of Finland (132473), the Finnish Cancer Society, and the Sigrid Juselius Foundation. Interdisciplinary Health Research International Team Breast Cancer Susceptibility (INHERIT BRCAs) was supported by the Canadian Institutes of Health Research for the "CIHR Team in Familial Risks of Breast Cancer" program and by the Canadian Breast Cancer Research Alliance-grant #019511.The Breast Cancer Family Registry (BCFR) was supported by the NCI, under RFA # CA-06-503, and through cooperative agreements with members of the BCFR and principal investigators, including Cancer Care Ontario (U01 CA69467), Cancer Prevention Institute of California (U01 CA69417), Columbia University (U01 CA69398), Fox Chase Cancer Center (U01 CA69631), Huntsman Cancer Institute (U01 CA69446), and University of Melbourne (U01 CA69638). The Australian BCFR was also supported by the National Health and Medical Research Council of Australia, the New South Wales Cancer Council, the Victorian Health Promotion Foundation (Australia), and the Victorian Breast Cancer Research Consortium. M.C. Southey is an NHMRC Senior Research Fellow and a Victorian Breast Cancer Research Consortium Group Leader. J.L. Hopper is an Australia Fellow of the NHMRC and a Victorian Breast Cancer Research Consortium Group Leader. Carriers at FCCC were also identified with support from the NITA grants P01 CA16094 and R01 CA22435. The New York BCFR was also supported by National Institutes of Health grants P30 CA13696 and P30 ES009089. The Utah BCFR was also supported by the National Center for Research Resources and the National Center for Advancing Translational Sciences, NIH Grant UL1 RR025764, and by Award Number P30 CA042014 from the NCI. Kathleen Cuningham Consortium for Research into Familial Breast Cancer (KCONFAB) is funded by NHMRC grants 145684, 288704, and 454508. A.B. Spurdle is supported by an NHMRC Senior Research Fellowship, and G-CT by an NHMRC Senior Principal Research Fellowship. National Cancer Institute (NCI): P.L. Mai, J.T. Loud, and M.H. Greene were funded by the Intramural Research Program of the US NCI at the NIH with infrastructure support from contracts NO2-CP-11019-50 and N02-CP-65504 with Westat, Inc. Mayo Clinic Study (MAYO) was supported by NIH R01278978 and grants from the Breast cancer Research Foundation and the Komen Foundation for the Cure. The Hereditary Breast and Ovarian Cancer Research Group Netherlands (HEBON) study is supported by the Dutch Cancer Society grants NKI1998-1854, NKI2004-3088, NKI2007-3756, and the ZonMW grant 91109024. OSU CCG: This work was funded by the OSU Comprehensive Cancer Center.